查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2004211

細胞和基因治療市場：2026-2032年全球市場預測（按治療方法、給藥途徑、治療領域、應用和最終用戶分類）

Cell & Gene Therapy Market by Therapy Type, Delivery Method, Therapeutic Areas, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，細胞和基因治療市場價值將達到 194.7 億美元，到 2026 年將成長至 229.8 億美元，到 2032 年將達到 713.8 億美元，複合年成長率為 20.39%。

主要市場統計數據
基準年 2025 194.7億美元
預計年份：2026年 229.8億美元
預測年份 2032 713.8億美元
複合年成長率 (%) 20.39%

簡明策略框架闡述了科學進步、製造複雜性增加以及政策趨勢如何重塑細胞和基因治療生態系統。

細胞和基因治療生態系統正處於轉折點，科學突破與營運和商業的複雜性交織在一起。載體工程、基因編輯精準性和過繼性細胞技術的進步已將曾經的理論治療方法轉變為臨床現實。同時，相關人員面臨著生產瓶頸、專業的低溫運輸物流以及不斷變化的監管預期，這需要產業界、學術界和服務供應商協調應對。

隨著技術、營運、監管和商業因素的交匯，細胞和基因治療領域的相關人員正在面臨哪些新的策略挑戰？

細胞和基因療法領域的格局正在以多種相互關聯的方式轉變，重新定義競爭優勢。技術進步提高了治療的特異性和持久性，而基因編輯平台和載體設計的創新則減少了脫靶效應，並拓展了治療應用範圍。同時，生產製造也從客製化的小批量生產流程轉向更標準化、模組化的方法，優先考慮穩健性、可重複性和成本控制。這種營運模式的演變使得新一代的契約製造組織（CMO）和平台供應商能夠提供可擴展的解決方案。

評估近期關稅政策變化對先進治療方法供應鏈、製造本地化和風險管理策略的多方面影響。

美國在2025年實施的關稅調整將為細胞和基因治療產業帶來新的複雜性，尤其因為該產業依賴來自世界各地的原料和跨境生產鏈。試劑、特殊原料和某些生物製藥成分的關稅可能會迫使採購團隊重新評估其供應商關係和庫存策略。對於依賴少數關鍵供應商的企業而言，關稅將獎勵選擇替代供應商，並將部分供應鏈本地化，以降低成本波動和海關延誤帶來的影響。

基於細分市場的分析揭示了治療方法、給藥途徑、適應症、用例和最終用戶概況如何影響商業性和營運選擇。

深入的市場區隔能夠清楚展現臨床潛力與實際營運的交會點，幫助領導者精準地分配資源。依治療方法類型分析市場，可以揭示清晰的研發和生產路徑。細胞療法分為幹細胞療法和T細胞療法，其中幹細胞療法可細分為造血幹細胞療法和間間質幹細胞療法。 T細胞療法則分為CAR-T細胞療法和T細胞受體療法。基因療法又引入了另一個細分維度：體外基因療法和基因治療，二者各自擁有獨特的載體、遞送方法和安全性特徵，這些因素都會影響研發進度和監管互動。

區域戰略趨勢和基礎設施因素對確定臨床開發、生產能力和市場進入舉措具有重要意義。

區域趨勢對整個細胞和基因治療領域的研發策略、監管環境和供應鏈設計都具有深遠的影響。在美洲，創新叢集匯聚了臨床專業知識、先進的製造能力和創業投資資金生態系統，從而支持快速轉化研究；同時，相關人員必須應對複雜的支付方環境和各州不同的政策。該地區的監管環境既嚴格強調臨床證據，又允許有條件核准的早期准入途徑。在營運方面，接近性關鍵學術機構有利於建立夥伴關係，從而加速早期臨床試驗。

專注於整合、平台專業化和卓越服務的企業策略如何重塑其在整個細胞和基因治療價值鏈中的競爭地位。

企業層面的策略正趨向一系列核心能力，這些能力將決定先進療法領域的贏家和輸家。主要企業正在投資垂直整合的能力，涵蓋藥物發現、載體和細胞工程、製程開發以及商業化規模生產，同時保持靈活的夥伴關係，以實現產能的快速擴張。其他企業則專注於平台技術，例如模組化生產系統、高效價載體生產和封閉式細胞處理系統，並透過許可或以合約服務形式運作這些技術，利用規模和可重複性創造價值。

領導者可採取的策略重點，以加強供應鏈韌性、擴大生產規模、協調監管策略並加快支付方採用。

產業領導者應優先考慮一系列切實可行的舉措，將科學優勢轉化為永續的商業性成功。首先，加強與供應商的夥伴關係，並採用雙重採購策略來確保臨床供應的連續性，同時降低地緣政治因素和關稅波動帶來的風險。其次，投資模組化生產能力和自動化技術可以減少批次間差異，提高單位成本，並擴大內部生產和契約製造夥伴關係的選擇範圍。此外，制定清晰的監管溝通計劃，納入真實世界數據策略和核准後數據收集，將有助於加快與支付方的對話，並支持基於結果的合約模式。

嚴謹的混合研究途徑，結合與關鍵相關人員的訪談、監管和專利分析以及流程圖繪製，檢驗了營運和策略見解。

本分析整合了多方面的證據，建構了細胞和基因治療領域當前趨勢的穩健且可重複的視圖。主要調查包括對藥物研發機構、臨床開發團隊、生產和供應鏈負責人、監管事務專家以及支付方的結構化訪談。次要調查則利用了同行評審文獻、公開的監管指南、臨床試驗註冊資訊、企業資訊披露資訊、專利申請以及物流和低溫運輸的研究，從多個角度檢驗了營運和科學趨勢。

一項綜合評估，將科學進步與營運準備和商業性途徑聯繫起來，以確保患者能夠持續獲得治療，並實現業務的永續永續性。

細胞和基因治療領域已進入一個新階段，在這個階段，不僅科學創新，策略執行也將決定哪些治療方法能產生持久的臨床和商業性影響。科學進步不斷拓展可治療疾病的範圍，並提高治療的精準度，但要將這些療法惠及患者，需要各方齊心協力，共同擴大生產規模、構建穩健的供應鏈、確保合規性，並為支付方提供充分的證據。那些積極建立穩健的供應商網路、採用模組化生產和數位化品管體系，並以可信的、基於真實世界證據的故事與支付方溝通的領導者，將更有能力將臨床成功轉化為廣泛的患者群體。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依治療方法的細胞和基因治療市場

  • 細胞療法
    • 幹細胞療法
      • 造血幹細胞療法
      • 間質幹細胞療法
    • T細胞療法
      • CAR-T細胞療法
      • 基於T細胞受體（TCR）
  • 基因治療
    • 體外基因治療
    • 體內基因治療

第9章：細胞與基因治療市場：依給藥方式分類

  • 肌肉內部
  • 靜脈

第10章：按治療領域分類的細胞和基因治療市場

  • 循環系統
    • 鬱血性心臟衰竭
    • 缺血性心臟疾病
  • 代謝性疾病
    • 糖尿病
    • 肥胖
  • 神經系統疾病
    • 阿茲海默症
    • 亨丁頓舞蹈症
    • 多發性硬化症
    • 帕金森氏症
    • 脊髓損傷
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 淋巴瘤
    • 固態腫瘤
  • 眼科

第11章 細胞與基因治療市場：依應用領域分類

  • 臨床應用
    • 疾病預防
    • 疾病治療
  • 研究與開發

第12章 細胞與基因治療市場：依最終用戶分類

  • 學術和研究機構
    • 私人研究機構
    • 大學
  • 醫院和診所

第13章 細胞與基因治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 細胞與基因治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 細胞與基因治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國細胞與基因治療市場

第17章：中國細胞與基因治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • AGC Inc.
  • Alnylam Pharmaceuticals, Inc.
  • American Gene Technologies Inc.
  • Amgen Inc.
  • AnGes, Inc
  • Astellas Pharma Inc.
  • Becton, Dickinson and Company
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • BridgeBio Pharma, Inc.
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Cellectis SA
  • CRISPR Therapeutics AG
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck KGaA
  • Moderna, Inc.
  • Mustang Bio, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • REGENXBIO Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Shoreline Biosciences
  • Sibiono GeneTech Co. Ltd.
  • Syncona Limited
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-450A0628CE5A

The Cell & Gene Therapy Market was valued at USD 19.47 billion in 2025 and is projected to grow to USD 22.98 billion in 2026, with a CAGR of 20.39%, reaching USD 71.38 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 19.47 billion
Estimated Year [2026] USD 22.98 billion
Forecast Year [2032] USD 71.38 billion
CAGR (%) 20.39%

A concise strategic framing of how scientific advances, manufacturing complexity, and policy dynamics are reshaping the cell and gene therapy ecosystem

The cell and gene therapy ecosystem stands at an inflection point where scientific breakthroughs are converging with operational and commercial complexity. Advances in vector engineering, gene editing precision, and adoptive cell technologies have moved previously theoretical interventions into clinical reality. At the same time, stakeholders are grappling with manufacturing bottlenecks, specialized cold-chain logistics, and evolving regulatory expectations that require coordinated responses across industry, academia, and service providers.

This executive summary distills the strategic implications of these shifts for leaders who must balance innovation with scale. It synthesizes emerging technology trajectories, supply chain vulnerabilities, payer and health system dynamics, and the policy environment shaping cross-border activity. The intent is to equip decision-makers with a clear narrative and practical lenses to evaluate near-term operational priorities and medium-term strategic options. By linking technical advances to commercial and regulatory realities, the analysis clarifies where investments and partnerships are most likely to deliver differentiated value.

Throughout this summary, emphasis is placed on executable insights rather than abstract trends, enabling teams to align R&D roadmaps, manufacturing investments, and go-to-market strategies with the most consequential drivers of success in the current landscape.

How converging technological, operational, regulatory, and commercial forces are creating new strategic imperatives for cell and gene therapy stakeholders

The landscape for cell and gene therapies is transforming along multiple, interlocking dimensions that together redefine competitive advantage. Technological advances are improving specificity and durability of treatments, with innovations in gene-editing platforms and vector design reducing off-target effects and broadening therapeutic applicability. Concurrently, manufacturing is transitioning from bespoke, small-batch processes to more standardized modular approaches that prioritize robustness, reproducibility, and cost control. This operational evolution is enabling a new class of contract manufacturing organizations and platform providers to offer scalable solutions.

Regulatory frameworks are adapting to accommodate rapid scientific progress, increasingly emphasizing real-world evidence, adaptive trial designs, and lifecycle oversight models. Payer engagement is also maturing, with outcome-based contracting and installment payment structures emerging as viable mechanisms to bridge high upfront costs and long-term clinical value. Geopolitical and trade dynamics are prompting sponsors to reassess supply chain strategies, driving interest in regional manufacturing and supplier diversification. As a result, partnerships and network orchestration are becoming central strategic levers: companies that can integrate discovery, development, and delivery across a distributed value chain while retaining control of core intellectual property will gain advantage.

Taken together, these shifts favor organizations that can couple scientific excellence with operational discipline, regulatory acuity, and commercial creativity, enabling therapies to move from promising science to sustainable patient access.

Assessing the multifaceted effects of recent tariff policy changes on supply chains, manufacturing localization, and risk management strategies in advanced therapies

The implementation of tariff changes in the United States in 2025 introduces a new layer of complexity for the cell and gene therapy sector, particularly because the industry relies on globally sourced inputs and cross-border manufacturing chains. Tariffs on reagents, specialized raw materials, and certain biologics components can drive procurement teams to re-evaluate supplier relationships and inventory strategies. For organizations dependent on a narrow set of critical suppliers, tariffs increase the incentive to qualify alternate suppliers or to localize portions of the supply chain to mitigate cost volatility and customs-related delays.

Beyond direct cost impacts, tariff policy influences capital allocation decisions related to manufacturing geography. Firms are increasingly weighing the trade-offs between building regional production capacity and maintaining centralized facilities that benefit from scale. Tariffs can accelerate regionalization by making domestic or nearshore production economically more attractive, but they can also fragment supply networks and amplify the need for redundant validation streams. Logistics flows are likewise affected: customs processing times and additional documentation requirements can stress cold-chain integrity for temperature-sensitive products, prompting greater investment in contingency transport options and quality monitoring across transit.

Strategically, the tariff environment will push companies to deepen upstream engagement with suppliers, to pursue integrated sourcing strategies that combine contractual protections with dual sourcing, and to enhance scenario planning that models policy shifts. For regulators and industry associations, the implications include a greater call for dialogue to ensure that trade measures do not inadvertently impede patient access or innovation by introducing excessive administrative burden. In sum, tariffs shape not only cost structures but also the architecture of global manufacturing and risk management for cell and gene therapy programs.

A segmentation-driven synthesis revealing how therapy modality, delivery route, therapeutic indication, application use case, and end-user profile shape commercial and operational choices

Insightful segmentation clarifies where clinical promise intersects with operational realities and allows leaders to prioritize resources with precision. When the market is parsed by therapy modality, distinct development and manufacturing pathways emerge: cell therapies divide into stem cell approaches and T cell-based approaches, with stem cell therapies further delineated into hematopoietic stem cell therapies and mesenchymal stem cell therapies, while T cell strategies separate into CAR T cell therapy and T cell receptor-based approaches. Gene therapies introduce another axis of differentiation, distinguishing ex vivo gene therapy from in vivo gene therapy, each carrying unique vector, delivery, and safety profiles that influence development timelines and regulatory interactions.

Delivery method segmentation underscores differences in clinical implementation and patient management, with intramuscular and intravenous approaches presenting divergent requirements for administration training, infusion capacity, and monitoring. Therapeutic area segmentation highlights how disease biology drives modality choice and commercial pathways: cardiovascular applications focus on congestive heart failure and ischemic heart disease, metabolic disorder efforts emphasize diabetes and obesity, neurological programs concentrate on conditions such as Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, and spinal cord injuries, and oncology initiatives pivot across hematological malignancies, lymphomas, and solid tumors. Application-based segmentation separates clinical applications from research and development activities, with the former further parsed into disease prevention and disease treatment, reflecting differing regulatory endpoints and payer expectations. Finally, end-user segmentation recognizes divergent purchasing and adoption dynamics between academic and research institutes and hospitals and clinics, with academic and research institutes further distinguished into private research labs and universities that shape investigator-initiated studies and translational pipelines.

Understanding these overlapping segments enables more targeted clinical trial design, manufacturing footprint planning, and commercialization strategies by aligning technical capabilities with the specific regulatory, clinical, and payer pathways associated with each segment.

Regional strategic dynamics and infrastructure considerations that determine where to locate clinical development, manufacturing capacity, and market access initiatives

Regional dynamics exert a powerful influence on development strategies, regulatory approaches, and supply chain design across the cell and gene therapy landscape. In the Americas, innovation clusters concentrate clinical expertise, advanced manufacturing capabilities, and venture funding ecosystems that support rapid translational activity, but stakeholders must manage complex payer landscapes and heterogeneous state-level policies. The regulatory environment in the region reflects an emphasis on rigorous clinical evidence combined with early access pathways that can facilitate conditional approvals; operationally, proximity to major academic centers supports partnerships that accelerate early-phase trials.

The Europe, Middle East & Africa region presents a mosaic of regulatory models and reimbursement systems. While some European jurisdictions offer collaborative assessment frameworks and health technology assessment pathways that reward long-term value, others require extensive local evidence generation. The region's manufacturing landscape is evolving with investments in capacity and specialized service providers, yet companies navigating this geography must reconcile cross-border regulatory variances and diverse healthcare funding mechanisms. Capacity-building initiatives and public-private partnerships are increasingly important levers to expand access in parts of the region where infrastructure remains nascent.

Asia-Pacific combines rapidly maturing clinical trial capabilities with ambitious national strategies to become hubs for biotechnology manufacturing and commercialization. Governments across the region are investing in biotechnology infrastructure, streamlined regulatory pathways for advanced therapies, and talent development programs. This creates both opportunity and complexity: sponsors can access large patient populations and lower development costs, but must also adapt to different regulatory expectations, local manufacturing requirements, and market access criteria.

Attuning strategy to these regional differences is essential for aligning trial design, manufacturing placement, and commercial access plans with local regulatory realities and payer expectations.

How company strategies focused on integration, platform specialization, and service excellence are reshaping competitive positioning across the cell and gene therapy value chain

Company-level strategies are converging around a set of core capabilities that differentiate winners from also-rans in the advanced therapy arena. Leading organizations are investing in vertically integrated capabilities that span discovery, vector and cell engineering, process development, and commercial-scale manufacturing, while also maintaining flexible partnerships that allow rapid capacity expansion. Others are specializing in platform technologies-such as modular manufacturing systems, high-titer vector production, or closed-system cell processing-that they can license or operate as contract services, thereby capturing value through scale and reproducibility.

Service providers and contract manufacturers are playing an increasingly strategic role by offering end-to-end solutions that reduce time-to-clinic for sponsors and lower technical risk. Companies that excel in quality systems, regulatory compliance, and supply chain orchestration are securing long-term relationships with sponsors by guaranteeing throughput and minimizing release delays. Meanwhile, developers are differentiating through clinical program design, biomarker-driven patient selection, and payer engagement strategies that translate clinical benefit into credible health economic narratives.

Investor and corporate development activity is focused on capabilities that address the industry's most pressing bottlenecks: scalable vector production, automation of cell handling, robust analytics for potency and comparability, and digitized batch record systems. Across these company archetypes, success correlates with the ability to demonstrate reproducible manufacturing, credible clinical outcomes, and a commercialization plan that accounts for reimbursement complexity and international market entry barriers.

Actionable strategic priorities for leaders to strengthen supply resilience, scale manufacturing, align regulatory strategy, and accelerate payer adoption

Industry leaders should prioritize a set of pragmatic actions to translate scientific advantage into durable commercial success. First, strengthening supplier partnerships and dual sourcing for critical inputs will mitigate exposure to geopolitical and tariff-driven disruptions while enabling continuity of clinical supply. Simultaneously, investing in modular manufacturing capabilities and automation can reduce batch variability and improve unit economics, creating optionality for both in-house production and contract manufacturing partnerships. In parallel, establishing clear regulatory engagement plans that incorporate real-world evidence strategies and post-approval data collection will accelerate payer conversations and support outcome-based contracting models.

Operationally, organizations should accelerate digitalization of quality systems and batch analytics to enable more predictive manufacturing control and faster regulatory submissions. Cross-functional alignment between R&D, manufacturing, and commercial teams is essential: integrated project governance that links clinical milestones to manufacturing readiness and market access requirements will reduce delays during transition to late-stage development. Collaboration with healthcare providers to design feasible administration pathways-particularly for complex cell therapies requiring specialized infusion centers-will ensure patient access and streamline adoption.

Finally, scenario-based strategic planning that models tariff outcomes, regulatory shifts, and capacity constraints will help leadership teams prioritize investments and partnership choices. By combining supply chain resilience, manufacturing scalability, regulatory foresight, and payer-focused evidence generation, industry leaders can de-risk development pathways and create sustainable routes to patient access.

A rigorous mixed-methods research approach that combines primary stakeholder interviews, regulatory and patent analysis, and process mapping to validate operational and strategic insights

This analysis synthesizes multiple evidence streams to construct a robust and reproducible view of current dynamics in the cell and gene therapy sector. Primary research included structured interviews with stakeholders across discovery organizations, clinical development teams, manufacturing and supply chain leaders, regulatory affairs experts, and payers. Secondary research drew on peer-reviewed literature, publicly available regulatory guidance, clinical trial registries, company disclosures, patent filings, and logistics and cold-chain studies to triangulate operational and scientific trends.

Analytical methods included process mapping of manufacturing workflows to identify common bottlenecks, comparative regulatory analysis to surface jurisdictional variances, and qualitative coding of expert interviews to highlight recurring strategic themes. Scenario analysis was employed to evaluate the operational implications of tariff changes and supply chain disruptions. Where appropriate, findings were validated through cross-checks with subject matter experts to reduce bias and ensure technical accuracy. Limitations include the pace of innovation in the field, which can create rapid shifts in capability and regulation, and the variability of proprietary manufacturing processes that limit direct comparability across all developers.

Despite these constraints, the methodology emphasizes triangulation and expert validation to produce insights that are actionable for strategic decision-making, investment evaluation, and operational planning.

Concluding synthesis that links scientific progress to operational readiness and commercial pathways for achieving durable patient access and business sustainability

The cell and gene therapy field is entering a phase where strategic execution, not just scientific novelty, will determine which therapies achieve lasting clinical and commercial impact. Scientific advances continue to expand the range of treatable conditions and improve the precision of interventions, yet the path to patients demands concerted attention to manufacturing scale-up, supply chain robustness, regulatory alignment, and payer evidence generation. Leaders who proactively build resilient supplier networks, adopt modular manufacturing and digital quality systems, and engage payers with credible real-world evidence narratives will be best positioned to translate clinical success into broad patient access.

The interplay of regional regulatory approaches, tariff dynamics, and commercial models means that global strategies must be flexible and locally adapted. Organizations that blend platform investments with smart partnerships and that apply scenario planning to geopolitical and policy changes will reduce execution risk. Above all, integrating scientific, operational, and commercial planning across the organization will accelerate transitions from demonstration to widespread adoption, ensuring therapies reach the patients who need them while maintaining sustainable business models.

Taken together, these priorities offer a practical roadmap for converting innovation into impact in a competitive and rapidly evolving environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Market, by Therapy Type

  • 8.1. Cell Therapy
    • 8.1.1. Stem Cell Therapies
      • 8.1.1.1. Hematopoietic Stem Cell Therapies
      • 8.1.1.2. Mesenchymal Stem Cell Therapies
    • 8.1.2. T Cell Therapy
      • 8.1.2.1. CAR T Cell Therapy
      • 8.1.2.2. T Cell Receptor (TCR)-based
  • 8.2. Gene Therapy
    • 8.2.1. Ex Vivo Gene Therapy
    • 8.2.2. In Vivo Gene Therapy

9. Cell & Gene Therapy Market, by Delivery Method

  • 9.1. Intramuscular
  • 9.2. Intravenous

10. Cell & Gene Therapy Market, by Therapeutic Areas

  • 10.1. Cardiovascular
    • 10.1.1. Congestive Heart Failure
    • 10.1.2. Ischemic Heart Disease
  • 10.2. Metabolic Disorders
    • 10.2.1. Diabetes
    • 10.2.2. Obesity
  • 10.3. Neurological Disorders
    • 10.3.1. Alzheimer's Disease
    • 10.3.2. Huntington's Disease
    • 10.3.3. Multiple Sclerosis
    • 10.3.4. Parkinson's Disease
    • 10.3.5. Spinal Cord Injuries
  • 10.4. Oncology
    • 10.4.1. Hematological Malignancies
    • 10.4.2. Lymphomas
    • 10.4.3. Solid Tumors
  • 10.5. Ophthalmology

11. Cell & Gene Therapy Market, by Application

  • 11.1. Clinical Applications
    • 11.1.1. Disease Prevention
    • 11.1.2. Disease Treatment
  • 11.2. Research & Development

12. Cell & Gene Therapy Market, by End User

  • 12.1. Academic & Research Institutes
    • 12.1.1. Private Research Labs
    • 12.1.2. Universities
  • 12.2. Hospitals & Clinics

13. Cell & Gene Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell & Gene Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell & Gene Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cell & Gene Therapy Market

17. China Cell & Gene Therapy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Abeona Therapeutics Inc.
  • 18.7. Adaptimmune Therapeutics PLC
  • 18.8. AGC Inc.
  • 18.9. Alnylam Pharmaceuticals, Inc.
  • 18.10. American Gene Technologies Inc.
  • 18.11. Amgen Inc.
  • 18.12. AnGes, Inc
  • 18.13. Astellas Pharma Inc.
  • 18.14. Becton, Dickinson and Company
  • 18.15. Biogen Inc.
  • 18.16. Bluebird Bio, Inc.
  • 18.17. BridgeBio Pharma, Inc.
  • 18.18. Bristol-Myers Squibb Company
  • 18.19. C.H. Boehringer Sohn AG & Co. KG
  • 18.20. Cellectis SA
  • 18.21. CRISPR Therapeutics AG
  • 18.22. F. Hoffmann-La Roche AG
  • 18.23. Gilead Sciences, Inc.
  • 18.24. Intellia Therapeutics, Inc.
  • 18.25. Ionis Pharmaceuticals, Inc.
  • 18.26. Johnson & Johnson Services Inc.
  • 18.27. Kyowa Kirin Co., Ltd.
  • 18.28. Merck KGaA
  • 18.29. Moderna, Inc.
  • 18.30. Mustang Bio, Inc.
  • 18.31. Novartis AG
  • 18.32. Novo Nordisk A/S
  • 18.33. Pfizer, Inc.
  • 18.34. REGENXBIO Inc.
  • 18.35. Sangamo Therapeutics, Inc.
  • 18.36. Sarepta Therapeutics, Inc.
  • 18.37. Shoreline Biosciences
  • 18.38. Sibiono GeneTech Co. Ltd.
  • 18.39. Syncona Limited
  • 18.40. Thermo Fisher Scientific Inc.
  • 18.41. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL & GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELL & GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CELL & GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CELL & GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 274. GCC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. GCC CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. GCC CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. GCC CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 278. GCC CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. GCC CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. GCC CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 281. GCC CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 282. GCC CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 283. GCC CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 284. GCC CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 285. GCC CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. GCC CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. GCC CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 288. GCC CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. GCC CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MIL